Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Ningshao Xia(Xiamen University), Zehong Huang(Xiamen University), Yuemei Hu(Jiangsu Provincial Center for Disease Control and Prevention), Chunlan Zhuang(Xiamen University), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Changgui Li(National Institutes for Food and Drug Control), Guohua Zhong(South China Agricultural University), Xia Zang, Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Jiali Quan(Xiamen University), Xiangzhong Ye(Beijing Wantai Biological Pharmacy (China)), Qi Chen(Xiamen University), Xiaohui Liu(Ministry of Ecology and Environment), Yixin Chen(China Pharmaceutical University), Liang Zhang(Xiamen University), Jun Zhang(Army Medical University), Changlin Yang, Junyu Chen(Xinjiang Medical University), Hong Sun(Johnson & Johnson (Israel)), Jinle Han(Beijing Wantai Biological Pharmacy (China)), Kai Chu(Jiangsu Provincial Center for Disease Control and Prevention), Hui Zhao(National Institutes for Food and Drug Control), Yingying Su(Xiamen University), Donglin Liu, Qiaoqiao Song(Beijing Wantai Biological Pharmacy (China)), Shoujie Huang(Xiamen University), Jingxin Li(Beijing Tongren Hospital), Han-Min Jiang, Tianying Zhang(Guangdong Medical College), Hong‐Yan Lin(Xiamen University), Ting Wu(Xiamen University)
The Lancet Respiratory Medicine
May 26, 2022
Cited by 140


Related Papers